FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309017231> ?p ?o ?g. }

• W4309017231 endingPage "vii79" @default.
• W4309017231 startingPage "vii78" @default.
• W4309017231 abstract "Abstract PURPOSE When brain cancer relapses, treatment options are scarce. The use of molecularly matched targeted therapies may provide a feasible and efficacious way to treat individual patients based on the molecular tumor profile. Since little information is available on this strategy in neuro-oncology, we retrospectively analyzed the clinical course of 41 patients who underwent advanced molecular testing at disease relapse. METHODS We performed Sanger sequencing, targeted next generation sequencing, and immunohistochemistry for analysis of potential targets, including programmed death ligand 1, cyclin D1, phosphorylated mechanistic Target of Rapamycin, telomerase reverse transcriptase promoter mutation, cyclin-dependent kinase inhibitor 2A/B deletion, or BRAF-V600E mutation. In selected patients, whole exome sequencing was conducted. RESULTS The investigation included 41 patients of which 32 had isocitrate dehydrogenase (IDH) wildtype glioblastoma. Molecular analysis revealed actionable targets in 31 of 41 tested patients and 18 patients were treated accordingly (matched therapy group). Twenty-three patients received molecularly unmatched empiric treatment (unmatched therapy group). In both groups, 16 patients were diagnosed with recurrent IDH wildtype glioblastoma. The number of severe adverse events was comparable between the therapy groups. Regarding the IDH wildtype glioblastoma patients, median progression-free survival (mPFS) and median overall survival (mOS) were longer in the matched therapy group (mPFS: 3.8 versus 2.0 months, p = 0.0057; mOS: 13.0 versus 4.3 months, p = 0.0357). CONCLUSIONS These encouraging data provide a rationale for molecularly matched targeted therapy in glioma patients. For further validation, future study designs need to additionally consider prevalence and persistence of actionable molecular alterations in patient tissue." @default.
• W4309017231 created "2022-11-20" @default.
• W4309017231 creator A5001167896 @default.
• W4309017231 creator A5004075000 @default.
• W4309017231 creator A5026784314 @default.
• W4309017231 creator A5031780975 @default.
• W4309017231 creator A5033900071 @default.
• W4309017231 creator A5041144526 @default.
• W4309017231 creator A5043495754 @default.
• W4309017231 creator A5046201684 @default.
• W4309017231 creator A5046639150 @default.
• W4309017231 creator A5050699846 @default.
• W4309017231 creator A5051467826 @default.
• W4309017231 creator A5052523213 @default.
• W4309017231 creator A5071494218 @default.
• W4309017231 creator A5071888326 @default.
• W4309017231 creator A5074474133 @default.
• W4309017231 creator A5074697803 @default.
• W4309017231 creator A5081762389 @default.
• W4309017231 date "2022-11-01" @default.
• W4309017231 modified "2023-10-18" @default.
• W4309017231 title "CTNI-34. PRECISION NEURO-ONCOLOGY - A PILOT ANALYSIS OF PERSONALIZED TREATMENT IN RECURRENT GLIOMA" @default.
• W4309017231 doi "https://doi.org/10.1093/neuonc/noac209.299" @default.
• W4309017231 hasPublicationYear "2022" @default.
• W4309017231 type Work @default.
• W4309017231 citedByCount "0" @default.
• W4309017231 crossrefType "journal-article" @default.
• W4309017231 hasAuthorship W4309017231A5001167896 @default.
• W4309017231 hasAuthorship W4309017231A5004075000 @default.
• W4309017231 hasAuthorship W4309017231A5026784314 @default.
• W4309017231 hasAuthorship W4309017231A5031780975 @default.
• W4309017231 hasAuthorship W4309017231A5033900071 @default.
• W4309017231 hasAuthorship W4309017231A5041144526 @default.
• W4309017231 hasAuthorship W4309017231A5043495754 @default.
• W4309017231 hasAuthorship W4309017231A5046201684 @default.
• W4309017231 hasAuthorship W4309017231A5046639150 @default.
• W4309017231 hasAuthorship W4309017231A5050699846 @default.
• W4309017231 hasAuthorship W4309017231A5051467826 @default.
• W4309017231 hasAuthorship W4309017231A5052523213 @default.
• W4309017231 hasAuthorship W4309017231A5071494218 @default.
• W4309017231 hasAuthorship W4309017231A5071888326 @default.
• W4309017231 hasAuthorship W4309017231A5074474133 @default.
• W4309017231 hasAuthorship W4309017231A5074697803 @default.
• W4309017231 hasAuthorship W4309017231A5081762389 @default.
• W4309017231 hasBestOaLocation W43090172311 @default.
• W4309017231 hasConcept C104317684 @default.
• W4309017231 hasConcept C121608353 @default.
• W4309017231 hasConcept C126322002 @default.
• W4309017231 hasConcept C127848430 @default.
• W4309017231 hasConcept C142724271 @default.
• W4309017231 hasConcept C143998085 @default.
• W4309017231 hasConcept C163763905 @default.
• W4309017231 hasConcept C181199279 @default.
• W4309017231 hasConcept C2777150147 @default.
• W4309017231 hasConcept C2778227246 @default.
• W4309017231 hasConcept C2780739268 @default.
• W4309017231 hasConcept C2781230642 @default.
• W4309017231 hasConcept C3019894029 @default.
• W4309017231 hasConcept C501734568 @default.
• W4309017231 hasConcept C502942594 @default.
• W4309017231 hasConcept C54355233 @default.
• W4309017231 hasConcept C55493867 @default.
• W4309017231 hasConcept C71924100 @default.
• W4309017231 hasConcept C76818968 @default.
• W4309017231 hasConcept C86803240 @default.
• W4309017231 hasConceptScore W4309017231C104317684 @default.
• W4309017231 hasConceptScore W4309017231C121608353 @default.
• W4309017231 hasConceptScore W4309017231C126322002 @default.
• W4309017231 hasConceptScore W4309017231C127848430 @default.
• W4309017231 hasConceptScore W4309017231C142724271 @default.
• W4309017231 hasConceptScore W4309017231C143998085 @default.
• W4309017231 hasConceptScore W4309017231C163763905 @default.
• W4309017231 hasConceptScore W4309017231C181199279 @default.
• W4309017231 hasConceptScore W4309017231C2777150147 @default.
• W4309017231 hasConceptScore W4309017231C2778227246 @default.
• W4309017231 hasConceptScore W4309017231C2780739268 @default.
• W4309017231 hasConceptScore W4309017231C2781230642 @default.
• W4309017231 hasConceptScore W4309017231C3019894029 @default.
• W4309017231 hasConceptScore W4309017231C501734568 @default.
• W4309017231 hasConceptScore W4309017231C502942594 @default.
• W4309017231 hasConceptScore W4309017231C54355233 @default.
• W4309017231 hasConceptScore W4309017231C55493867 @default.
• W4309017231 hasConceptScore W4309017231C71924100 @default.
• W4309017231 hasConceptScore W4309017231C76818968 @default.
• W4309017231 hasConceptScore W4309017231C86803240 @default.
• W4309017231 hasIssue "Supplement_7" @default.
• W4309017231 hasLocation W43090172311 @default.
• W4309017231 hasOpenAccess W4309017231 @default.
• W4309017231 hasPrimaryLocation W43090172311 @default.
• W4309017231 hasRelatedWork W2179871824 @default.
• W4309017231 hasRelatedWork W2233554087 @default.
• W4309017231 hasRelatedWork W2329357574 @default.
• W4309017231 hasRelatedWork W2900130860 @default.
• W4309017231 hasRelatedWork W3158810716 @default.
• W4309017231 hasRelatedWork W4224283047 @default.
• W4309017231 hasRelatedWork W4291162324 @default.
• W4309017231 hasRelatedWork W4308977249 @default.
• W4309017231 hasRelatedWork W4309017231 @default.

• next